Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06795009 · ClinicalTrials.gov registry record · Phase 1
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
A Phase 1 study of Endometrial Cancer and Uterine Cancer, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT06795009: Recruiting Phase 1 study of Endometrial Cancer and Uterine Cancer, sponsored by Washington University School of Medicine.
NCT06795009 is a Phase 1 study of Endometrial Cancer and Uterine Cancer that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 36 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06795009, a Phase 1 study of Endometrial Cancer and Uterine Cancer, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Zanzalintinib
Study Locations (4)
California
- University of California, San Francisco - San Francisco
Missouri
- Washington University School of Medicine - St Louis
New Mexico
- University of New Mexico - Albuquerque
Oklahoma
- University of Oklahoma - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-10-17 |
| Est. Completion | 2035-04-30 |
| Phase | Phase 1 |
What NCT06795009 shows while recruiting
NCT06795009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT06795009 reports a single indexed study location in California, Missouri, New Mexico.
Frequently Asked Questions
What is clinical trial NCT06795009 about?
NCT06795009 is a clinical study titled "Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer". The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
What is the current status of trial NCT06795009?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-10-17. Estimated completion is 2035-04-30.
What conditions does trial NCT06795009 study?
This clinical trial studies the following conditions: Endometrial Cancer, Uterine Cancer.
What interventions are being tested in trial NCT06795009?
The interventions under investigation include: Paclitaxel (DRUG), Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT06795009?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06795009 being conducted?
This trial has 4 study locations across California, Missouri, New Mexico, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06795009's enrollment target sits among peer trials
36 141st of 181 higher than 40 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI